LatestIP And Trademarks 22 July 2026
Novo Nordisk Patent Dispute
Novo Nordisk's semaglutide patent is being weighed in court, with the Indian generics manufacturer challenging the patent's validity, specifically Indian Patent 262697, which was granted for an invention titled Acylated GLP-1, and the court will consider the obviousness of the invention and its implications for the pharmaceutical industry, as the Indian generics manufacturer seeks to produce a generic version of semaglutide
The court is considering the validity of Novo Nordisk's semaglutide patent, which could have significant implications for the pharmaceutical industry. The key points in the dispute include:
- The Indian generics manufacturer is challenging the patent's validity,
- The court will consider the obviousness of the invention,
- The outcome of the case could impact the production of generic versions of semaglutide.
The case highlights the ongoing challenges faced by pharmaceutical companies in protecting their patents and the importance of intellectual property rights in the industry.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.